Hoe verhoudt 2MT0's PS Ratio zich tot zijn concurrenten?

2MT0 is een goede waarde op basis van zijn Price-To-Sales Ratio (0.1x) vergeleken met het gemiddelde van gelijken (14.6x).

Hoe verhoudt 2MT0's PS Ratio zich tot andere bedrijven in de DE Biotechs industrie?

2MT0 is een goede waarde op basis van de Price-To-Sales -ratio ( 0.1 x) vergeleken met het German Biotechs -industriegemiddelde ( 12.6 x).

Wat is 2MT0's PS Ratio vergeleken met zijn Fair PS Ratio? Dit is de verwachte PS Ratio, rekening houdend met de verwachte winstgroei van het bedrijf, winstmarges en andere risicofactoren.

2MT0 is een goede waarde op basis van de Price-To-Sales -ratio ( 0.1 x) vergeleken met de geschatte eerlijke Price-To-Sales -ratio ( 0.9 x).

Wat is de reële prijs van 2MT0 als we kijken naar de toekomstige kasstromen? Voor deze schatting gebruiken we een Discounted Cash Flow-model.

Onvoldoende gegevens om de reële waarde van 2MT0 te berekenen voor waarderingsanalyse.

Wat is de 12-maandsprognose van de analisten en hebben we enig statistisch vertrouwen in het consensuskoersdoel?

Er zijn onvoldoende gegevens om een prijsvoorspelling te tonen.

Athenex (DB:2MT0) - Aandelenkoers, Nieuws & Analyse

2MT0 Overzicht aandelen

Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. Meer informatie

2MT0 fundamentele analyse
Sneeuwvlok Score
Waardering	3/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	0/6
Dividenden	0/6

Beloningen

Handelen tegen een goede waarde vergeleken met branchegenoten en branchegenoten

Risicoanalyse

Heeft geen betekenisvolle marktkapitalisatie ( €10M )

Negatief eigen vermogen

Aandeelhouders zijn het afgelopen jaar substantieel verwaterd

Aandelen zijn zeer illiquide

+ 2 meer risico's

Athenex, Inc. Concurrenten

co.don

XTRA:CNW

€6.5m

Medigene

XTRA:MDG1

€20.6m

Bellicum Pharmaceuticals

BST:BPXA

€772.4k

Heidelberg Pharma

XTRA:HPHA

€106.7m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Athenex
Historische aandelenkoersen
Huidige aandelenkoers	US$3.27
52 Week Hoogtepunt	US$22.77
52 Week Laag	US$1.43
Bèta	1.35
11 maand verandering	0%
3 maanden verandering	-3.31%
1 Jaar Verandering	-65.09%
33 jaar verandering	-98.24%
5 jaar verandering	-98.85%
Verandering sinds IPO	-98.87%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	2MT0	DE Biotechs	DE Markt
7D	0%	0.8%	0.8%
1Y	-65.1%	-18.3%	8.6%

Rendement versus industrie: 2MT0 presteerde slechter dan de German Biotechs -sector, die het afgelopen jaar een rendement van -18.3 % opleverde.

Rendement versus markt: 2MT0 presteerde slechter dan German Market, dat het afgelopen jaar een rendement van 8.6 % opleverde.

Prijsvolatiliteit

Is 2MT0's price volatile compared to industry and market?
2MT0 volatility
2MT0 Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.5%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Stabiele aandelenkoers: 2MT0 heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van 2MT0 in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2003	275	Johnson Lau	www.athenex.com

Athenex, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Athenex zich tot de beurswaarde?
2MT0 fundamentele statistieken
Marktkapitalisatie	€9.10m
Inkomsten(TTM)	-€90.28m
Inkomsten(TTM)	€94.74m

0.1x

P/S-verhouding

-0.1x

Koers/Winstverhouding

Is 2MT0 overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
2MT0 resultatenrekening (TTM)
Inkomsten	US$102.82m
Kosten van inkomsten	US$76.12m
Brutowinst	US$26.70m
Overige uitgaven	US$124.68m
Inkomsten	-US$97.98m

Laatst gerapporteerde inkomsten

Dec 31, 2022

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-11.31
Brutomarge	25.97%
Nettowinstmarge	-95.29%
Schuld/Eigen Vermogen Verhouding	-511.7%

Hoe presteerde 2MT0 op de lange termijn?

Bekijk historische prestaties en vergelijking

2MT0 Overzicht aandelen

Beloningen

Risicoanalyse

Athenex, Inc. Concurrenten

XTRA:CNW

€6.5m

XTRA:MDG1

€20.6m

BST:BPXA

€772.4k

XTRA:HPHA

€106.7m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Athenex, Inc. Announces the Separation of Joe Annoni as Assistant Chief Restructuring Officer

Nasdaq to Delist the Common Stock of Athenex

Athenex, Inc.(OTCPK:ATNX.Q) dropped from NASDAQ Composite Index

Athenex, Inc. announced delayed 10-Q filing

Nasdaq Staff Determines Athenex's Common Stock to be Delisted from Nasdaq as a Result of the Chapter 11 Case

Athenex, Inc.(NasdaqGS:ATNX) dropped from S&P TMI Index

Recent updates

Athenex, Inc. Announces the Separation of Joe Annoni as Assistant Chief Restructuring Officer

Nasdaq to Delist the Common Stock of Athenex

Athenex, Inc.(OTCPK:ATNX.Q) dropped from NASDAQ Composite Index

Athenex, Inc. announced delayed 10-Q filing

Nasdaq Staff Determines Athenex's Common Stock to be Delisted from Nasdaq as a Result of the Chapter 11 Case

Athenex, Inc.(NasdaqGS:ATNX) dropped from S&P TMI Index

Motion for Asset Sale Filed by Athenex, Inc.

Athenex Receives Letter from the Listing Qualifications Staff of the Nasdaq as the Company No Longer Meets Nasdaq Listing Rule 5450(b)(3)(C)

Athenex Announces Reverse Stock Split

Athenex Announces MHRA Decision on Oral Paclitaxel

Athenex, Inc. Announces Quantum Leap Healthcare Collaborative Reports Positive Trial Result of I-SPY2 Trial for Oral Paclitaxel in Combination with PD-1 and Carboplatin in Neoadjuvant Breast Cancer

Insufficient new directors

Third quarter 2022 earnings released: US$0.14 loss per share (vs US$0.33 loss in 3Q 2021)

Athenex Announces Receipt of Positive Nasdaq Listing Determination

Athenex, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Athenex Receives Written Notification from Nasdaq Stating the Company Had Not Regained Compliance with the Rule and Was Ineligible to Obtain A Second 180 Calendar Day Period to Regain Compliance

Athenex, Inc. has completed a Follow-on Equity Offering in the amount of $29.995333 million.

Dr. Reddy's, Intas Reportedly in Talks to Buy Athenex

Second quarter 2022 earnings released: US$0.21 loss per share (vs US$0.33 loss in 2Q 2021)

Athenex, Inc. to Report Q2, 2022 Results on Jul 28, 2022

TiHe Capital (Beijing) Co. Ltd. agreed to acquire Chongqing Taihao Pharmaceutical Co., Ltd. and Athenex Pharmaceuticals (Chongqing) Limited from Athenex, Inc. (NasdaqGS:ATNX) for CNY 124 million.

Athenex, Inc. Appoints Darrel P. Cohen, MD, PhD as Chief Medical Officer of Cell Therapy to Lead Its Clinical Development, Clinical Operations, and Regulatory Affairs Functions

Insufficient new directors

Athenex, Inc. Provides Sales Guidance for the Full Year 2022

First quarter 2022 earnings released: US$0.27 loss per share (vs US$0.27 loss in 1Q 2021)

Insufficient new directors

Athenex, Inc. to Report Q1, 2022 Results on May 10, 2022

Athenex Presents Interim Data from Phase 1 ANCHOR Study of KUR-502 (Allogeneic CD19 CAR-NKT Cells) in Relapsed or Refractory Lymphoma and Leukemia at the 2022 Transplantation & Cellular Meetings of ASTCT and CIBMTR

Kim Campbell Not to Stand for Re-Election to the Athenex Board of Directors At the 2022 Annual Meeting of Stockholders

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Athenex Announces Appoints Joe Annoni as Chief Financial Officer

ImmunityBio, Inc. (NasdaqGS:IBRX) completed the acquisition of Dunkirk Manufacturing Facility and Certain Related Assets of Athenex, Inc. (NasdaqGS:ATNX).

Athenex, Inc. Announces UK MHRA Validation of the Marketing Authorization Application for Oral Paclitaxel and Encequidar for Review

Athenex to Present Subgroup Analysis from Phase 3 Study of Oral Paclitaxel Plus Encequidar (KX-ORAX-001) in Metastatic Breast Cancer At SABCS 2021

Independent Director recently bought €54k worth of stock

Third quarter 2021 earnings released: US$0.33 loss per share (vs US$0.44 loss in 3Q 2020)

Independent Director recently bought €136k worth of stock

Chief Financial Officer Randoll Sze has left the company

Second quarter 2021 earnings released: US$0.33 loss per share (vs US$0.50 loss in 2Q 2020)

Athenex, Inc. Presents Data on Oral Docetaxel and Oral Paclitaxel at ASCO2021 Virtual Scientific Program

Athenex, Inc. Announces Klisyri® (Tirbanibulin) Receives Positive Chmp Opinion from the European Medicines Agency (Ema) for the Treatment of Actinic Keratosis of the Face or Scalp

Athenex, Texas Children’s Cancer Center, and the Center for Cell and Gene Therapy at Baylor College of Medicine Present New Clinical Data on GD2 CAR-NKTCells in Neuroblastoma at ASGCT Annual Meeting

First quarter 2021 earnings released: US$0.27 loss per share (vs US$0.24 loss in 1Q 2020)

Athenex, Inc. Reaffirms Sales Guidance for the Year 2021

Athenex, Inc. (NasdaqGS:ATNX) acquired Kuur Therapeutics Limited.

Zhang Investor Law Alerts Investors of Deadline in Securities Class Action Lawsuit Against Athenex, Inc

Robbins LLP Reminds Shareholders that Athenex, Inc. is Being Sued for Misleading Shareholders

Insider recently sold €1.6m worth of stock

Independent Director recently sold €385k worth of stock

The Schall Law Firm Announces the Filing of A Class Action Lawsuit Against Athenex, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Athenex Receives FDA Complete Response Letter for Oral Paclitaxel Plus Encequidar for the Treatment of Metastatic Breast Cancer

Full year 2020 earnings released: US$1.72 loss per share (vs US$1.67 loss in FY 2019)

New 90-day low: €4.52

Revenue beats expectations

Athenex, Inc. to Report Q4, 2020 Results on Mar 01, 2021

Athenex, Inc. Enters into Second Amendment to the License Agreement

Athenex Announces New England Journal of Medicine Publication of Phase III Data on the Efficacy and Safety of Klisyri® (tirbanibulin)

New 90-day high: €11.80

Athenex Announces FDA Approval of Klisyri® (Tirbanibulin) for the Treatment of Actinic Keratosis on the Face or Scalp